Skip to main content

Main menu

  • Home
  • Content
    • Current
      • JNMT Supplement
    • Ahead of print
    • Past Issues
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Permissions
    • Continuing Education
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine Technology
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine Technology

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Permissions
    • Continuing Education
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook
  • Join SNMMI on LinkedIn
  • Subscribe to JNMT RSS feeds
Research ArticleRadionuclide Therapy

Analysis of Residence Time, Effective Half-Life, and Internal Dosimetry Before Radioiodine Therapy

Caio Vinicius Oliveira, Tatiane Sabriela Cagol Camozzato, Patricia Fernanda Dorow and Jéssica Pasqueta
Journal of Nuclear Medicine Technology September 2022, 50 (3) 233-239; DOI: https://doi.org/10.2967/jnmt.121.263502
Caio Vinicius Oliveira
Federal Institute of Education, Science, and Technology of Santa Catarina, Florianópolis, Santa Catarina, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tatiane Sabriela Cagol Camozzato
Federal Institute of Education, Science, and Technology of Santa Catarina, Florianópolis, Santa Catarina, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricia Fernanda Dorow
Federal Institute of Education, Science, and Technology of Santa Catarina, Florianópolis, Santa Catarina, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jéssica Pasqueta
Federal Institute of Education, Science, and Technology of Santa Catarina, Florianópolis, Santa Catarina, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Radioiodine therapy has been widely used for ablation of remnant tissue after surgical treatment of differentiated thyroid carcinoma (DTC). Internal dosimetry provides a new approach to choosing the administered activity—an approach that considers the distribution and retention of 131I individually per patient. This study used clinical techniques of internal dosimetry to assess the accumulated activity, internal bone marrow dosimetry, and effective half-life in patients undergoing treatment for DTC. Methods: This was a quantitative, retrospective study analyzing diagnostic documents and images. The internal dosimetry method calculated the dose absorbed by the bone marrow per administered activity of 131I. Calculation of the absorbed dose took into account the accumulated activity, which was obtained through measurements of whole-body images acquired at 4 intervals over 5 d. Results: The median dose absorbed by the bone marrow per administered activity was 0.117 mGy/MBq (range, 0.043–0.152 mGy/MBq). The median whole-body residence time was 22.0 h (range, 12.6–39.4 h). The median effective half-life was 15.6 h (range, 7.6–28.2 h). Conclusion: Internal dosimetry provides information relevant to safe dose limits for DTC radioiodine therapy, especially in advanced cases of the disease for which greater activities may be necessary.

  • nuclear medicine
  • dosimetry
  • radiometry
  • thyroid gland neoplasms
  • iodine radioisotopes

Footnotes

  • Published online Jun. 14, 2022.

View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Login to the site using your SNMMI member credentials

Individuals

Non-Member Login

Login as an individual user

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine Technology: 50 (3)
Journal of Nuclear Medicine Technology
Vol. 50, Issue 3
September 1, 2022
  • Table of Contents
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Analysis of Residence Time, Effective Half-Life, and Internal Dosimetry Before Radioiodine Therapy
(Your Name) has sent you a message from Journal of Nuclear Medicine Technology
(Your Name) thought you would like to see the Journal of Nuclear Medicine Technology web site.
Citation Tools
Analysis of Residence Time, Effective Half-Life, and Internal Dosimetry Before Radioiodine Therapy
Caio Vinicius Oliveira, Tatiane Sabriela Cagol Camozzato, Patricia Fernanda Dorow, Jéssica Pasqueta
Journal of Nuclear Medicine Technology Sep 2022, 50 (3) 233-239; DOI: 10.2967/jnmt.121.263502

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Analysis of Residence Time, Effective Half-Life, and Internal Dosimetry Before Radioiodine Therapy
Caio Vinicius Oliveira, Tatiane Sabriela Cagol Camozzato, Patricia Fernanda Dorow, Jéssica Pasqueta
Journal of Nuclear Medicine Technology Sep 2022, 50 (3) 233-239; DOI: 10.2967/jnmt.121.263502
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Review of Palliative 223Ra in Metastatic Castration-Resistant Prostate Cancer: Experience at West Virginia University Cancer Center
  • Analysis of Radiometry on Patients Undergoing Radioactive Iodine Therapy
Show more Radionuclide Therapy

Similar Articles

Keywords

  • nuclear medicine
  • Dosimetry
  • Radiometry
  • Thyroid gland neoplasms
  • Iodine radioisotopes
SNMMI

© 2023 Journal of Nuclear Medicine Technology

Powered by HighWire